Michael W Handlogten

20130309699, Nov 21, 2013

Jan 18, 2012

13/979919

Zihni Basar Bilgicer - Granger IN, US
Tanyel Kiziltepe Bilgicer - Granger IN, US
Nathan Joseph Alves - Woodbury CT, US
Jonathan Darryl Ashley - Olathe KS, US
Michael William Handlogten - Rochester MN, US

UNIVERSITY OF NOTRE DAME DU LAC - Notre Dame IN

C07K 1/22

435 794, 5303871, 5303889

Embodiments herein provide methods of purifying monoclonal and polyclonal anti-bodies (e.g., immunoglobulins) from biological fluids, such as cell lysates, cell supernatant and ascites fluids, using small molecule affinity chromatography. Various embodiments disclose a class of small molecules that selectively bind a nucleotide binding site that is inherent to all immunoglobulins, and in various embodiments, methods are disclosed that use one of these small molecules as a capture molecule in small molecule affinity chromatography. In some embodiments, the small molecule may be an indole, and in particular embodiments, the small molecule may be indole-3-butyric acid.

20210115157, Apr 22, 2021

Dec 18, 2020

17/126466

- South Bend IN, US
Peter Edward DEAK - South Bend IN, US
Tanyel KIZILTEPE BILGICER - South Bend IN, US
Michael William HANDLOGTEN - South Bend IN, US
Jonathan Darryl ASHLEY - South Bend IN, US

University of Notre Dame du Lac - South Bend IN

C07K 16/46
A61K 47/62
A61K 47/54
A61K 9/127
A61K 38/05
A61K 38/07
A61K 47/02
A61K 47/10

The invention provides a strategy for site specific covalent modification of antibodies using a specialized targeting covalent heterobivalent ligand (cHBL), and corresponding design for a covalent heterobivalent inhibitor (cHBI) that can be used to prevent Immunoglobulin E (IgE) mediated allergic reactions triggered by drug molecules, according to one embodiment. These molecules contain four important components: (1) an IgE antigen binding site (ABS) ligand that can be a mimotope for the allergen protein, a small molecule, or a peptidomimetic, (2) an appropriate linker, which can be any flexible or rigid chemical linker, providing spacing between the ABS binder and the other moieties, (3) a nucleotide binding site (NBS) ligand, and (4) a reactive moiety to form a covalent link with an amino acid side chain of target IgE antibodies.

20190375857, Dec 12, 2019

Dec 19, 2016

16/062832

- South Bend IN, US
Peter Edward DEAK - South Bend IN, US
Tanyel KIZILTEPE BILGICER - South Bend IN, US
Michael William HANDLOGTEN - South Bend IN, US
Jonathan Darryl ASHLEY - South Bend IN, US

University of Notre Dame du Lac - South Bend IN

C07K 16/46
A61K 47/02
A61K 47/10
A61K 47/54
A61K 47/62
A61K 38/05
A61K 38/07
A61K 9/127

The invention provides a strategy for site specific covalent modification of antibodies using a specialized targeting covalent heterobivalent ligand (cHBL), and corresponding design for a covalent heterobivalent inhibitor (cHBI) that can be used to prevent Immunoglobulin E (IgE) mediated allergic reactions triggered by drug molecules, according to one embodiment. These molecules contain four important components: (1) an IgE antigen binding site (ABS) ligand that can be a mimotope for the allergen protein, a small molecule, or a peptidomimetic, (2) an appropriate linker, which can be any flexible or rigid chemical linker, providing spacing between the ABS binder and the other moieties, (3) a nucleotide binding site (NBS) ligand, and (4) a reactive moiety to form a covalent link with an amino acid side chain of target IgE antibodies.

20190112357, Apr 18, 2019

May 9, 2017

16/300315

- Gaithersburg MD, US
Wai Keen CHUNG - Gaithersburg MD, US
Deborah Sweet GOLDBERG - Gaithersburg MD, US
Michael HANDLOGTEN - Gaithersburg MD, US
Someet NARANG - Gaithersburg MD, US
Brian RUSSELL - Gaithersburg MD, US
Min ZHU - Gaithersburg MD, US
Suzanne HUDAK - Gaithersburg MD, US
Kenneth HWANG - Gaithersburg MD, US
Jihong WANG - Gaithersburg MD, US

C07K 16/00

Disclosed are methods for testing the presence and/or activity of glutathione system components and thioredoxin system components during the manufacturing process of disulfide bond-containing proteins. Also disclosed are methods for mitigating reduction of disulfide bonds during the manufacturing process, and for lowering the reduction potential of disulfide bond-containing proteins. Provided are compositions, kits, and methods for mitigating reduction and diminishing reduction potential of disulfide bond-containing proteins during protein manufacturing processes.

20180177810, Jun 28, 2018

Jan 23, 2018

15/878295

- South Bend IN, US
Tanyel KIZILTEPE BILGICER - South Bend IN, US
Jonathan Darryl ASHLEY - South Bend IN, US
Jared Francis STEFANICK - South Bend IN, US
Nathan J. ALVES - South Bend IN, US
Michael W. HANDLOGTEN - South Bend IN, US

University of Notre Dame du Lac - South Bend IN

A61K 31/704
A61K 51/04
A61K 31/351
A61K 47/69
A61K 47/62
A61K 9/107

Embodiments provide systems, methods, and compositions for nanoparticle-based drug delivery to target cells or tissues. A drug delivery system may include a nanoparticle with a targeting component and a therapeutic component. The nanoparticle may have a predetermined number or valence of targeting molecules for multivalent interaction with a target cell or tissue. Binding of the targeting molecules to the target cell may result in receptor-mediated uptake of the nanoparticle by the target cell. The therapeutic component may be subsequently released within an endocytic vesicle of the target cell. Nanoparticle-based drug delivery systems as described herein may provide improved efficacy and/or reduced toxicity.

20170166607, Jun 15, 2017

Feb 17, 2017

15/436650

Zihni Basar Bilgicer - Granger IN, US
Tanyel Kiziltepe Bilgicer - Granger IN, US
Nathan Joseph Alves - Woodbury CT, US
Jonathan Darryl Ashley - Olathe KS, US
Michael William Handlogten - Rochester MN, US

UNIVERSITY OF NOTRE DAME DU LAC - South Bend IN

C07K 1/22
C07K 16/00

Embodiments herein provide methods of purifying monoclonal and polyclonal anti-bodies (e.g., immunoglobulins) from biological fluids, such as cell lysates, cell supernatant and ascites fluids, using small molecule affinity chromatography. Various embodiments disclose a class of small molecules that selectively bind a nucleotide binding site that is inherent to all immunoglobulins, and in various embodiments, methods are disclosed that use one of these small molecules as a capture molecule in small molecule affinity chromatography. In some embodiments, the small molecule may be an indole, and in particular embodiments, the small molecule may be indole-3-butyric acid.

20140287049, Sep 25, 2014

Nov 5, 2012

14/356121

- Notre Dame IN, US
Tanyel Kiziltepe Bilgicer - Granger IN, US
Jonathan Darryl Ashley - Olathe KS, US
Jared Stefanick - Mishawaka IN, US
Nathan J. Alves - Woodbury CT, US
Michael W. Handlogten - Rochester MN, US

A61K 31/704
A61K 47/48

424489, 514 34

Embodiments provide systems, methods, and compositions for nanoparticle-based drug delivery to target cells or tissues. A drug delivery system may include a nanoparticle with a targeting component and a therapeutic component. The nanoparticle may have a predetermined number or valence of targeting molecules for multivalent interaction with a target cell or tissue. Binding of the targeting molecules to the target cell may result in receptor-mediated uptake of the nanoparticle by the target cell. The therapeutic component may be subsequently released within an endocytic vesicle of the target cell. Nanoparticle-based drug delivery systems as described herein may provide improved efficacy and/or reduced toxicity.